Advocacy Group Questions Medanta MD Naresh Trehan’s Panel Appointment

The Working Group on Access to Medicines and Treatments has asked the Department of Pharmaceuticals to replace Medanta CMD Dr. Naresh Trehan from an expert panel.

The advocacy group argues that Dr. Trehan's financial interests and association with the Medanta Group create a potential conflict of interest impacting the panel's impartiality.

The Supreme Court-directed committee was constituted to examine regulatory frameworks for pharmaceutical marketing practices and the voluntary 2024 UCPMP code.